Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

KR-HT5 is based on Akoya’s PhenoImager® HT PlatformMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 -- Akoya Biosciences, Inc. , The Spatial Biology Company®, and Shanghai KR Pharmtech, a...

Related Keywords

China ,Shanghai ,Xuzhou ,Jiangsu ,Chinese ,Akoya Biosciences ,Brian Mckelligon ,Rui Zhang ,Akoya Bioscience ,Priyam Shah ,Akoya Phenoimager ,Spatial Biology Company ,Medicine Technology Research ,Nasdaq ,Exchange Commission ,China National Medical Products Administration ,Akoya Biosciences Inc ,Spatial Biology ,National Medical Products Administration ,Multispectral Imaging ,Next Generation Pathology ,Financial Condition ,Smart Medical Industry ,Next Generation Sequencing ,Investor Contact ,Media Contact ,Markets ,